Patients and pharmacists can now use smartphones to check biologics are genuine with a new Merck Serono tech launched to combat counterfeiters' growing interest in high-value biopharma drugs.
People on the Move
Novo Nordisk is reportedly searching for obesity experts to staff an R&D centre, Merck Serono gets a new CEO, and we look at the latest biopharmaceutical hires.
Strategic partnerships - always a hot-topic for CROs – are becoming almost exclusively a big issue for mid-sized biopharma, though small biopharma and large pharma companies are interested as well, Quintiles CEO Tom Pike said Monday at the Morgan Stanley...
People on the Move
Plus senior hires at Merck Serono, Astellas, the European Medicines Agency, and more.
Strategic partnerships are “flexible, cost-effective and will become the trend over the next few years,” says CRO DZS, which has signed a multi-year deal with SBI Pharmaceuticals.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
New hires at Merck Serono, Amgen, Takeda and Fate Therapeutics this week. It's in-Pharmatechnologist.com's people column.
Columbia Laboratories has reported strong annual results despite a fourth quarter affected by Actavis taking the manufacture of vaginal gel Crinone in-house and the “lumpiness” of Merck Serono.
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
Dispatches from PCT
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Merck Serono has announced plans to build an $80m plant for the production of diabetes and cardiovascular drugs in China.
Janet Woodcock is set to stay at the CDER despite rumours of her retirement, and there's a host of new appointments at Merck Serono - welcome to in-Pharmatechnologist's People on the Move.
Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono.
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
Sino-US CRO Pharmaron has signed a drug discovery partnership with Anglo-Swedish drug major AstraZeneca.
Merck Serono has inked a master services agreement with its recently spun-out biomarker analysis services firm Quartz Bio.
Merck Serono houses R&D lab at Chinese CRO’s campus
CRO Pharmaron is housing Merck Serono’s Chinese laboratory at its 600,000 sq ft Beijing campus as part of a partnership.
Appointments at Merck Serono, Ascletis, Allon, Acura, Sangamo and ProStrakan – People on the move
in-PharmaTechnologist.com presents its latest round up of movements in the pharma sector, including appointments at Merck Serono, Ascletis, Allon, Acura, Sangamo and ProStrakan.
Europe approves Merck Serono prefilled pen injectors
Merck Serono has received European approval for prefilled pen injectors designed to increase compliance during fertility treatment.
Merck Serono opens state-of-the-art research centre in Massachusetts.
EMD Serono Inc., an affiliate of pharma giant Merck, has announced the opening of a new research centre in Massachusetts, US.
Appointments at Catalent, Quintiles, ACM and Premier Research – People on the move
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Quintiles, ACM and Premier Research.
inVentiv buys Star Terre Santé for French pharma comms
inVentiv Health has acquired Star Terre Santé to expand its healthcare communications footprint into France.
Merck KGaA plans €150m clinical R&D centre in China
Merck KGaA says China’s growing drug market is the key driver for the new €150m ($224m) clinical R&D hub it plans to set up in Beijing.
Merck Serono expands biotech site
Merck Serono has begun work on the expansion of its Swiss biotech facility, with the additional capacity being used to meet rising demand for Erbitux (cetuximab).
Merck KGaA still has an eye to buy in pharma
Germany's Merck KGaA is still on the lookout for acquisitions or
in-licensing deals to fill out its pharmaceutical business
following the purchase and integration of Swiss biotech Serono.
Flamel tech used for Merck Serono drug
France-based Flamel Technologies and Merck Serono have shook hands
on a new €2m ($2.9m) deal which would see Flamel's Medusa
technology used to develop an extended-release profile of an
undisclosed therapeutic protein.
Merck KGaA pulls out of diabetes research
In a shock announcement at its third quarter financial results,
Merck KGaA has said it will stop its diabetes research and partner
out any current programmes.
EU approval of new Rebif just what the doctor ordered
Merck Serono's new and improved version of its blockbuster multiple
sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in
the EU, providing a little added protection to the company's MS
Reformulated Rebif right on track
Merck Serono's revised formulation of its top seller Rebif
(interferon beta-1a) that offers improved tolerability for multiple
sclerosis sufferers has received a positive opinion from the
Committee for Medicinal Products for...
Drugs moving into the clinic: 5
The fifth in a series of periodic roundups of drugs that have moved
from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to